WSW, NY, October 21st, 2026, FinanceWireRecent acquisitions and licensing deals reveal what drugmakers want next: different ...
Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE’s recent FDA and EU ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
Recent developments in the Prader-Willi syndrome treatment market, including progress on targeted therapies such as Rhythm ...
Add Yahoo as a preferred source to see more of our stories on Google. Seattle Children's Hospital Seattle Children's said a clinical trial published this week in The New England Journal of Medicine ...
Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show ...
The obesity market has been transformed by GLP-1 therapies, but the next phase of innovation is increasingly expanding beyond GLP-1 alone. One small biotechnology company positioned at the ...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results